GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akeso Inc (HKSE:09926) » Definitions » COGS-to-Revenue

Akeso (HKSE:09926) COGS-to-Revenue : 0.07 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Akeso COGS-to-Revenue?

Akeso's Cost of Goods Sold for the six months ended in Dec. 2023 was HK$61 Mil. Its Revenue for the six months ended in Dec. 2023 was HK$929 Mil.

Akeso's COGS to Revenue for the six months ended in Dec. 2023 was 0.07.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Akeso's Gross Margin % for the six months ended in Dec. 2023 was 93.40%.

Akeso COGS-to-Revenue Historical Data

The historical data trend for Akeso's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akeso COGS-to-Revenue Chart

Akeso Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
Get a 7-Day Free Trial - - 0.14 0.11 0.03

Akeso Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.32 0.17 0.10 0.02 0.07

Akeso COGS-to-Revenue Calculation

Akeso's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=145.744 / 4950.72
=0.03

Akeso's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=61.326 / 929.049
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akeso  (HKSE:09926) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Akeso's Gross Margin % for the six months ended in Dec. 2023 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 61.326 / 929.049
=93.40 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Akeso COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Akeso's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Akeso (HKSE:09926) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akeso Inc (HKSE:09926) » Definitions » COGS-to-Revenue
Comparable Companies
HKSE:09995 HKSE:01877 HKSE:01548 HKSE:06990 HKSE:01530 HKSE:06826 HKSE:02162 HKSE:01177 HKSE:09969 HKSE:01541 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
AKESF:USA 4RY:Germany
Address
6 Shennong Road, Torch Development Zone, Guangdong Province, Zhongshan, CHN, 528437
Website
https://www.akesobio.com
Akeso Inc is an investment holding company. The Company's subsidiaries were involved in research and development, production and commercialization of biopharmaceutical products. The company currently has a pipeline of over 30 drugs for the treatment of diseases like cancers, autoimmune diseases, inflammation and metabolic diseases, 17 of which have entered the clinical stage, including two first-in-class bi-specific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF). The majority of the company's revenue is earned in Mainland China.
Executives
Xia Yu 2501 Other
Wang Zhongmin Maxwell 2501 Other
Li Baiyong 2501 Other
Green Court Capital Holdings Limited 2201 Interest of corporation controlled by you
Green Court Capital Management Limited 2102 Investment manager
Green Court Management Holdings Llc 2201 Interest of corporation controlled by you
Yao Yulin 2201 Interest of corporation controlled by you
Shenzhen Capital Group Co., Ltd. 2201 Interest of corporation controlled by you
Xia Yu 2501 Other
Shen Zhen Shi Chuang Xin Tou Zi Ji Tuan You Xian Gong Si 2201 Interest of corporation controlled by you
Zheng Xun
Zhong Shan Shi Xun Xiang Gu Quan Tou Zi Guan Li Qi Ye You Xian He Huo
Cantrust (far East) Limited 2301 Trustee
Aquae Hyperion Limited 2101 Beneficial owner
Htkf Investments Limited 2101 Beneficial owner

Akeso (HKSE:09926) Headlines

No Headlines